As a result, obese individuals may engage in pathological eating as a way to compensate for the decreased reward response
Medical Eligibility Required Semaglutide cannot be prescribed to individuals with the following conditions: BMI under 27, eating disorders, Type 1 diabetes, gallbladder disease, substance abuse, recent bariatric surgery (within the past 6 months), pancreatitis or history of recurrent pancreatitis while taking a GLP-1 medication, medullary thyroid cancer, current pregnancy or breastfeeding, plans to become pregnant, diabetic retinopathy, multiple endocrine neoplasia type 2 (MEN2) or family history of MEN2, serious gastrointestinal disorders, or history of allergic reaction to Semaglutide
It has been proven that single NG neurons express multiple receptors for anorectic substances, for example GLP-1R, cholecystokinin A receptor, and leptin receptor 7,29 , but it remains unclear whether orexigenic GHSR coexists with anorectic receptors
Bloating and nausea are the most reported symptoms during the 0.5 mg transition, affecting roughly 25 to 30 percent of researchers